[Multicenter study comparing efficacy and tolerance of moclobemide and fluvoxamine in hospitalized and ambulatory patients with severe depressive episodes].
In a double blind study performed in psychiatric clinics the efficacy and tolerability of the new antidepressant Moclobemide was compared. Moclobemide belongs to a new class of substances called RIMA (Reversible Inhibitor of the monoamine oxidase type A). 61 patients with major depression (according to DSM-III) were either treated with Moclobemide or Fluvoxamine, a selective reuptake-inhibitor of 5-HT. The latter belongs to a class of antidepressants known for their better tolerability compared to tricyclic antidepressants. Moclobemide was as effective as Fluvoxamine but much better tolerated as shown by a lower incidence of side effects such as gastrointestinal problems or headache.
Barrelet
L
L
Hôpital Psychiatrique Cantonal, Perreux.
Blajev
B
B
Bolzani
L
L
de Saussure
C
C
Kasas
A
A
Van
H
H
Gachoud
J P
JP
D000328:Adult; D000368:Aged; D000928:Antidepressive Agents / Q000627:therapeutic use*; D001549:Benzamides / Q000009:adverse effects / Q000627:therapeutic use*; D003866:Depressive Disorder / Q000188:drug therapy*; D005260:Female; D016666:Fluvoxamine; D006801:Humans; D008297:Male; D008875:Middle Aged; D020912:Moclobemide; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use; D010091:Oximes / Q000009:adverse effects / Q000627:therapeutic use*; D012702:Serotonin Antagonists / Q000627:therapeutic use
D000928:Antidepressive Agents; D001549:Benzamides; D008996:Monoamine Oxidase Inhibitors; D010091:Oximes; D012702:Serotonin Antagonists; D016666:Fluvoxamine; D020912:Moclobemide
Etude multicentrique comparant l'efficacité et la tolérance du moclobémide et de la fluvoxamine chez des patients hospitalisés et ambulatoires présentant un épisode dépressif majeur.